XML 28 R16.htm IDEA: XBRL DOCUMENT
v3.23.2

ACCRUED AND OTHER CURRENT LIABILITIES | 6 Months Ended
--- | ---
Jun. 30, 2023
Payables and Accruals [Abstract] |
ACCRUED AND OTHER CURRENT LIABILITIES | ACCRUED AND OTHER CURRENT LIABILITIES Accrued and other current liabilities consist of:
(in millions) |  | June 30, 2023 |  | December 31, 2022
Employee compensation and benefit costs |  | $ | 191 |  |  | $ | 196 |
Product rebates |  | 145 |  |  | 153 |
Discounts and allowances |  | 82 |  |  | 85 |
Professional fees |  | 70 |  |  | 66 |
Product returns |  | 63 |  |  | 59 |
Other |  | 401 |  |  | 342 |
|  | $ | 952 |  |  | $ | 901 |
Under the terms of a December 2019 agreement with Novaliq GmbH, the Company is required to make future payments related to the future sales associated with MIEBO TM (formerly known as NOV03). On May 18, 2023, the U.S. Food and Drug Administration (“FDA”) approved the New Drug Application (“NDA”) for MIEBO TM and the Company accrued the $45 million milestone payment, which is included within Other, in the table above, as of June 30, 2023.

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration